Simtra BioPharma Solutions’ Post

CPHI #CPHIMilan starts tomorrow, and we’re excited to be in attendance.     Learn more about the Aprecia vision:  ➡️ Imagine: Create new solutions and new possibilities in the digital age of medicine. ➡️ Inspire: Never stop exploring ways to take medicine to its fullest potential.  ➡️ Transform: Establish 3DP technology as a true digital pharmaceutical manufacturing technology.   Stop by and see us at booth #16F4 to learn more.    #AtTheHeartOfPharma #3Dprintingtechnology #pharmaceuticaltechnology 

Stop by the Aprecia Pharmaceuticals booth today to discuss how our 3DP Pharmaceutical Manufacturing Technology can help to solve your formulation challenges.

Dear Esteemed Colleagues in the Pharmaceutical Industry, I trust this message finds you in good health and high spirits. I would like to convey my sincere best wishes to all esteemed peers who will be in attendance at CPhI Worldwide 2024 in Milan. The anticipation for the upcoming CPhI is palpable. I hope your participation in the event will yield fruitful outcomes, leading to the establishment of prosperous business partnerships for collective advancement. Given the limited timeframe of approximately 2.5 days for the event, it is imperative to thoughtfully arrange pre-scheduled meetings. Unfortunately, time constraints may restrict in-depth dialogues and the ability to meet all intended business associates. Nonetheless, we can leverage virtual platforms such as LinkedIn, telephone calls, WhatsApp, and Teams to engage in comprehensive discussions and interactions, transcending the constraints of physical meetings for those with whom an in-person meeting may not be feasible. While time is of the essence, it is crucial to nurture mutual understanding and cultivate robust professional relationships, recognizing each individual's pivotal role in the pharmaceutical landscape. I extend my sincere wishes for the success of all my colleagues at the upcoming CPhI 2024 event in Milan. Warm regards,

Let’s Meet and discuss how we can enhance global healthcare system ✨

There’s only 1 week remaining until our free advanced #ADME symposium + personalized workshop in Brussels, so reserve your spot today! Join us on April 11 for a tour of BioIVT’s lab in Belgium and hear experts present a variety of research topics and case studies. Then on April 12, attend a workshop to see product demonstrations and talk to experts about applications in your research. You can register to attend one or both dates: https://lnkd.in/e7eQTwB7 April 11 Presentations: - Carboxylesterases in Drug Metabolism: Challenges and Opportunities - A Human 3D Liver-Chip Model Composed of Primary Human Hepatocytes for Drug Safety and ADME Predictions - siRNA Delivery in a Long-Term Hepatic Micropatterned Co-Culture (HEPATOPAC): Methods and Applications - Understanding How a Transporter Allows an Acetylated Amino Acid to Act as a Drug - Drug-Drug Preclinical Interactions Studies: Merck Examples Spotting Importance of Design and Test Article Properties - Development of Antibody-Drug Conjugates: Safety and ADME Considerations April 12 workstations include #HEPATOPAC®️, cryoplated #hepatocytes, #BACTOSOMES®️ recombinant #enzymes, fresh tissue and more. Learn more and register: https://lnkd.in/e7eQTwB7 #druginteractions #drugtransporters #drugmetabolism #DMPK

Nerviplex Clinical Trial

Excited for these new developments in the clinical trial space! #Cytek #FullSpectrumProfiling (FSP) technology allows for more insights in clinical trials. Let’s discuss how we can work more closely with your group at #CYTO2024 this week

There are still seats remaining for the complimentary April 11 #ADME symposium and tour of BioIVT’s lab in Belgium. Network with colleagues and hear experts present a variety of research topics and case studies (see below). Then on April 12, attend a workshop to see product demonstrations and talk to experts about specific applications for your research. Register to attend one or both dates: https://lnkd.in/eh7qbFKr April 11 Presentations: - Carboxylesterases in Drug Metabolism: Challenges and Opportunities - A Human 3D Liver-Chip Model Composed of Primary Human Hepatocytes for Drug Safety and ADME Predictions - siRNA Delivery in a Long-Term Hepatic Micropatterned Co-Culture: Methods and Applications - Understanding How a Transporter Allows an Acetylated Amino Acid to Act as a Drug - Drug-Drug Preclinical Interactions Studies: Merck Examples Spotting Importance of Design and Test Article Properties - Development of Antibody-Drug Conjugates: Safety and ADME Considerations April 12 workstations include #HEPATOPAC®️, cryoplated #hepatocytes, #BACTOSOMES®️ recombinant #enzymes, fresh tissue and more. Learn more and register: https://lnkd.in/eh7qbFKr #druginteractions #drugtransporters #drugmetabolism #DMPK

⏳ Only a few days left until #SwissBiotechDay2024! Join our team, Emmanuel Chereul and Natalia NIEMIR-DEVEAU, PhD, at the Swiss Biotech Association Day to learn more about Voxcan, your CRO specialized in non-invasive high-resolution imaging for non-clinical drug development. Don’t hesitate to contact them to arrange a meeting. We look forward to meeting you and exploring how Voxcan can support your projects! See you there! #SwissBiotechDay2024 #lifescience #nonclinical #CRO #partnering #drugdevelopment #infectiousdiseases #oncology #osteoarticulardiseases #drugdiscovery 

Could phage-based diagnostics prevent a post-antibiotic future? Drug-resistant Tuberculosis accounts for 1 in 3 deaths from antimicrobial resistance (AMR)*, meaning grim predictions for a ‘post-antibiotic age’ are already a reality for many countries. This is why a ‘test-of-cure’ diagnostic to extend the life of new drugs is so urgently needed. Dr Ben Swift is speaking today at  #BioInfect2024 says Actiphage could provide breakthrough test-of-cure for TB treatment AMR expert Dr Ben Swift, R&D Director for PBD Biotech says: “Our phage-based diagnostic has potential to monitor the efficacy of drug treatment – something not possible with current technology – as well as offering the opportunity to identify antibiotic-resistant TB.”   He explains that AMR occurs when microorganisms causing disease no longer respond to the drugs. “One of the reasons that AMR has increased for TB is that the traditional treatments require multiple drugs, taken over extended time periods. It is therefore difficult for many communities to gain access to the right medication, and patient compliance can be low as the drugs have severe side-effects.”   Tuberculosis disease is fatal if untreated and only about 2 in 5 people with drug resistant TB accessed treatment in 2022. A further 3.1 million cases remain undetected each year. The most widely used test for TB relies on measuring the patient’s immune response, which occurs when the disease is well progressed; the test also cannot distinguish between active disease and past infection.   PBD Biotech has developed Actiphage TB, which takes advantage of the specificity of interaction between a phage and its host bacteria to create a rapid diagnostic for TB and other diseases caused by Mycobacteria.   Actiphage is currently in lab user trials by the R2D2 Network in the Philippines. The country has a high incidence of TB and, in 2021, was one of the first to adopt BPaL, a new short-protocol medicine for multidrug-resistant TB.   Dr Swift continues: “BPaL is a six-month treatment that has been hailed as a breakthrough in the fight to End TB. In parallel with the development of new drugs, it is vital that new diagnostics are developed to target them effectively.   “By making the bacterial DNA available for sequencing, Actiphage would enable an informed choice of treatment for the patient, reducing the risk of resistance. Additionally, as Actiphage detects only live mycobacteria it can also be used after the course of treatment as a test-of-cure and to support the development of new drugs.”   Dr Swift will be discussing the role of phage-based TB diagnostics in the ‘What’s in the pipeline’ session of BioInfect 2024 on Thursday 8th February 2024 at The Spine, Liverpool L7 3FA.   Further information for the event can be found at https://lnkd.in/e727TAEJ  #tuberculosis #EndTb. #Bionow. #Bioinfect #pathology   * https://lnkd.in/eZr9VC7v